)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
NeuroSense Therapeutics
NeuroSense Therapeutics (NRSN) investor relations material
NeuroSense Therapeutics Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary4 May, 2026
Clinical development and pipeline
Lead asset PrimeC is Phase 3-ready for ALS, with initiation expected mid-2026 and a robust pipeline targeting ALS, Alzheimer's, and Parkinson's diseases.
PrimeC has orphan drug designation and utilizes the expedited 505(b)(2) regulatory pathway.
PrimeC clinical results and efficacy
Phase 2b PARADIGM study showed PrimeC slowed ALS progression by 32.8% over 18 months (p=0.007) and improved survival by 65% (median survival difference ~15 months, p=0.02).
PrimeC demonstrated a favorable safety and tolerability profile, with most adverse events mild or moderate and only two transient serious events.
Early and continuous treatment with PrimeC led to better clinical outcomes, including significant improvements in bulbar and respiratory function.
Mechanism of action and biomarker engagement
PrimeC is a patented, fixed-dose combination of two approved drugs with synchronized release, targeting neuroinflammation, iron metabolism, and miRNA dysregulation.
Demonstrated significant modulation of ALS-linked miRNAs and iron metabolism biomarkers, correlating with clinical benefit.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from NeuroSense Therapeutics
- PrimeC slowed ALS progression by 32.8% and improved survival, advancing to Phase 3 in 2026.NRSN
Corporate presentation16 Apr 2026 - PrimeC showed significant ALS survival benefits as late-stage trials and regulatory steps advance.NRSNQ4 202531 Mar 2026
- PrimeC slowed ALS progression by 32.8% over 18 months and advances to Phase 3 in 2026.NRSNCorporate presentation16 Mar 2026
- PrimeC slowed ALS progression by 32.8% and improved survival by 58% in Phase 2b trials.NRSNCorporate presentation30 Jan 2026
- Biotech seeks $150M to advance ALS drug PrimeC amid ongoing losses and regional risks.NRSNRegistration Filing29 Jan 2026
- Advancing ALS therapy to Phase III, with recent financings and ongoing Nasdaq compliance risks.NRSNRegistration Filing16 Dec 2025
- ALS drug developer registers shares for resale amid financial and geopolitical challenges.NRSNRegistration Filing16 Dec 2025
- Advancing ALS therapy to Phase 3 with new funding, but faces Nasdaq and geopolitical risks.NRSNRegistration Filing16 Dec 2025
- PrimeC slowed ALS progression by 32.8% over 18 months and advances to Phase 3 in 2026.NRSNCorporate Presentation12 Dec 2025
Next NeuroSense Therapeutics earnings date
Q2 202631 Jul, 2026
NeuroSense Therapeutics
Next NeuroSense Therapeutics earnings date
Q2 202631 Jul, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage